Design Therapeutics (DSGN) EBIT Margin (2020)
Design Therapeutics (DSGN) posted quarterly EBIT Margin of 11700.0% for Q4 2020, up 1.8% on a QoQ basis from 11915.0% in Q3 2020.
Powered by 
Analysis
Design Therapeutics (DSGN) EBIT Margin (2020) Analysis & Trends
Design Therapeutics has reported EBIT Margin for 1 years, with the latest figure at 11700.0% in Q4 2020.
- EBIT Margin for Q4 2020 came in at 11700.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was 3685.84% (changed N/A YoY), and the FY2020 annual result was 3685.84%, changed N/A from the prior year.
- EBIT Margin grew to 11700.0% in Q4 2020, from 11915.0% in the prior quarter.
- Over five years, EBIT Margin peaked at 438.73% in Q1 2020 and troughed at 11915.0% in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -11,700.00% |
| Sep 30, 2020 | -11,915.00% |
| Jun 30, 2020 | -4,719.35% |
| Mar 31, 2020 | -438.73% |